Maze Therapeutics, Inc. (MAZE) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Maze Therapeutics reported revenue of $0. Net income was -$131.1M, or -$3.05 per diluted share. Operating activities generated -$111.9M of cash, leaving -$112.7M of free cash flow. At fiscal year end, Maze Therapeutics held $397.1M in total assets against $42.2M in total liabilities, including $189.2M of cash and equivalents.
Open the full interactive Maze Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Maze Therapeutics Key Stats
| Share Price | $26.66 |
|---|---|
| Market Cap | $1.57B |
| 52-Week Range | $22.39 – $51.83 |
| Shares Outstanding | 59.0 million (basic, 2026 Q2) |
Maze Therapeutics Income Statement
| FY 2025 | |
|---|---|
| Revenue | $0 |
| Operating Income | -$142.9M |
| Pre-Tax Income | -$131.1M |
| Income Tax | $0 |
| Net Income | -$131.1M |
| Diluted EPS | -$3.05 |
Maze Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $20.0M | $0 |
| Net Income | -$30.1M | -$34.6M | -$24.2M | -$44.7M |
| Diluted EPS | -$0.66 | -$0.80 | -$0.45 | -$0.76 |
Maze Therapeutics Balance Sheet
| FY 2025 | |
|---|---|
| Cash & Equivalents | $189.2M |
| Current Assets | $349.7M |
| Total Assets | $397.1M |
| Current Liabilities | $22.6M |
| Total Liabilities | $42.2M |
| Shareholders' Equity | $355.0M |
Maze Therapeutics Cash Flow Statement
| FY 2025 | |
|---|---|
| Cash From Operations | -$111.9M |
| Cash From Investing | -$171.0M |
| Cash From Financing | $275.3M |
| Free Cash Flow | -$112.7M |
Figures from Maze Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Maze Therapeutics financials page for every line item.
Maze Therapeutics Company Profile
| Ticker | MAZE |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | South San Francisco, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001842295 |
Frequently Asked Questions
What was Maze Therapeutics' revenue in fiscal 2025?
Maze Therapeutics (MAZE) reported revenue of $0 for fiscal 2025.
What was Maze Therapeutics' net income in fiscal 2025?
Maze Therapeutics reported net income of -$131.1M for fiscal 2025.
What was Maze Therapeutics' earnings per share (EPS) in fiscal 2025?
Maze Therapeutics' diluted EPS was -$3.05 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Maze Therapeutics generate in fiscal 2025?
Maze Therapeutics generated -$112.7M of free cash flow in fiscal 2025.
What was Maze Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Maze Therapeutics reported revenue of $0.
How many shares of Maze Therapeutics are outstanding?
Maze Therapeutics reported a weighted average of 59.0 million basic shares outstanding in 2026 Q2.
What is Maze Therapeutics' market cap?
Based on its latest closing price, Maze Therapeutics (MAZE) has a market capitalization of about $1.57B.
When does Maze Therapeutics' fiscal year end?
Maze Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Maze Therapeutics headquartered?
Maze Therapeutics lists its business address in South San Francisco, California in its SEC filings.
Maze Therapeutics Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →